Trinity Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	49.41	61.56	56.83	62.52	81.15
Revenue Growth (YoY)	-15.76%	8.31%	-9.10%	-22.96%	-
Cost of Revenue	32.7	40.11	37.38	45.25	47.7
Gross Profit	16.71	21.44	19.45	17.27	33.45
Selling, General & Admin	27.39	28.82	31.15	26.98	22.5
Research & Development	4.22	4.54	4.38	4.14	4.5
Other Operating Expenses	9.52	9.25	10.96	5.5	2.52
Total Operating Expenses	41.13	42.61	46.5	36.62	29.52
Operating Income	-24.1	-21.17	-27.05	-19.35	3.94
Interest Income	-0.05	-	1.17	0.3	1.22
Interest Expense	-10.9	-9.57	-11.05	-24.73	-7.09
Total Non-Operating Income (Expense)	-10.95	-9.57	-9.88	-24.43	-5.86
Pretax Income	-35.05	-30.73	-36.93	-43.78	-1.92
Provision for Income Taxes	0.85	0.49	-0.06	-0.19	-0.07
Net Income	-36.48	-31.79	-24.02	-41.01	0.88
Earnings From Discontinued Operations	-0.57	-0.57	12.85	2.58	2.73
Net Income to Common	-36.48	-31.79	-24.02	-41.01	0.88
Shares Outstanding (Basic)	15	18	8	7	4
Shares Outstanding (Diluted)	15	18	8	7	4
Shares Change (YoY)	79.92%	134.62%	13.46%	61.40%	-
EPS (Basic)	-2.54	-2.00	-4.00	-6.00	0.20
EPS (Diluted)	-2.54	-2.00	-4.00	-3.20	0.20
Shares Outstanding	18.63	17.96	7.67	1.52	0.84
Free Cash Flow	-5.22	-4.6	-12.36	-2.02	11.43
Free Cash Flow Per Share	-0.34	-0.26	-1.61	-0.30	2.73
Gross Margin	33.81%	34.83%	34.22%	27.62%	41.23%
Operating Margin	-48.78%	-34.38%	-47.59%	-30.95%	4.85%
Profit Margin	-72.66%	-50.71%	-64.87%	-69.71%	-2.28%
FCF Margin	-10.57%	-7.47%	-21.75%	-3.23%	14.08%
EBITDA	-21.79	-19.3	-25.27	-17.02	6.68
EBITDA Margin	-44.09%	-31.35%	-44.46%	-27.22%	8.23%
EBIT	-24.1	-21.17	-27.05	-19.35	3.94
EBIT Margin	-48.78%	-34.38%	-47.59%	-30.95%	4.85%
Effective Tax Rate	-2.42%	-1.58%	0.16%	0.44%	3.85%

SEC Filings: 10-K · 10-Q